nature.com

A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR…

Abstract

Prostate cancer (PCa) is an androgen-dependent malignancy, with HSP90 and HSP70 serving as classical molecular chaperones that maintain androgen receptor (AR) protein stability and regulate its transcriptional activation. Surprisingly, our study identified TOMM20, a mitochondrial outer membrane protein, as a potential molecular chaperone with similar roles to HSP90/HSP70. We found that TOMM20 expression is elevated in PCa tissues and cell lines and positively correlates with AR levels. RNA-seq analysis revealed that TOMM20 knockdown significantly reduced the mRNA levels of AR-regulated genes. Additionally, the protein level of KLK3 (PSA) decreased, and AR binding to the androgen response element (ARE) of the KLK3 promoter was diminished following TOMM20 knockdown, leading to decreased KLK3 gene transcription. Furthermore, TOMM20 depletion reduced both cytoplasmic and nuclear AR protein levels and facilitated AR degradation via an E3 ubiquitin ligase SKP2-mediated ubiquitin-proteasome pathway, independent of heat shock proteins (HSPs). To our knowledge, this is the first report demonstrating that TOMM20, a mitochondrial outer translocase protein, stabilizes AR protein and enhances its transcriptional activity, while its knockdown promotes AR degradation through the SKP2-mediated ubiquitin-proteasome pathway. These findings suggest that TOMM20 may serve as a potential biomarker for PCa progression and a promising therapeutic target for drug development.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Change institution

Buy or subscribe

Subscribe to this journal

Receive 50 print issues and online access

$259.00 per year

only $5.18 per issue

Learn more

Buy this article

Purchase on SpringerLink

Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Fig. 1: TOMM20 is overexpressed in prostate cancer (PCa) cells and tumor specimens.

Fig. 2: TOMM20 regulates AR regulatory genes.

Fig. 3: TOMM20 promotes AR-regulated KLK3 gene transcription.

Fig. 4: TOMM20 mantains AR protein stability, while TOMM20 knockdown promotes SKP2-mediated ubiquitination degradation of AR protein.

Fig. 5: TOMM20 knockdown decreased the levels of nuclear and cytoplasmic AR protein of prostate cancer cells.

Fig. 6: TOMM20 regulates AR regulatory genes through the mechanisms independent of HSP proteins.

Fig. 7: Schematic representation of mechanism of TOMM20 in the regulation of AR signaling pathway.

Data availability

The RNA-seq data in this manuscript have been submitted to the National Centre for Biotechnology (BioProject ID:PRJAN783133). The public datasets used in this study were downloaded from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) and the cBioPortal(http://www.cbioportal.org/). All relevant data are available from the corresponding authors upon reasonable request.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

ArticlePubMedGoogle Scholar

Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells 2020;9:2653.

Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992;14:113–30.

PubMedGoogle Scholar

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835–9.

ArticlePubMedPubMed CentralGoogle Scholar

Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995;5:97–125.

ArticlePubMedGoogle Scholar

Fang Y, Fliss AE, Robins DM, Caplan AJ. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem. 1996;271:28697–702.

ArticlePubMedGoogle Scholar

Dong J, Wu Z, Wang D, Pascal LE, Nelson JB, Wipf P, et al. Hsp70 binds to the androgen receptor N-terminal domain and modulates the receptor function in prostate cancer cells. Mol Cancer Ther. 2019;18:39–50.

ArticlePubMedGoogle Scholar

Georget V, Terouanne B, Nicolas JC, Sultan C. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry. 2002;41:11824–31.

ArticlePubMedGoogle Scholar

Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006;231:12–19.

ArticlePubMedGoogle Scholar

Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev. 2016;37:3–15.

PubMedPubMed CentralGoogle Scholar

Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2015;12:26–36.

ArticlePubMedGoogle Scholar

Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, et al. High mitochondria content is associated with prostate cancer disease progression. Mol Cancer. 2013;12:145.

ArticlePubMedPubMed CentralGoogle Scholar

Masciangelo R, Chiti MC, Camboni A, Amorim CA, Donnez J, Dolmans MM. Mitochondrial content, activity, and morphology in prepubertal and adult human ovaries. J Assist Reprod Genet. 2021;38:2581–90.

ArticlePubMedPubMed CentralGoogle Scholar

Sayyed UMH, Mahalakshmi R. Mitochondrial protein translocation machinery: From TOM structural biogenesis to functional regulation. J Biol Chem. 2022;298:101870.

ArticlePubMedPubMed CentralGoogle Scholar

Zhao Z, Han F, He Y, Yang S, Hua L, Wu J, et al. Stromal-epithelial metabolic coupling in gastric cancer: stromal MCT4 and mitochondrial TOMM20 as poor prognostic factors. Eur J Surg Oncol. 2014;40:1361–8.

ArticlePubMedGoogle Scholar

Park SH, Lee AR, Choi K, Joung S, Yoon JB, Kim S. TOMM20 as a potential therapeutic target of colorectal cancer. BMB Rep. 2019;52:712–7.

ArticlePubMedPubMed CentralGoogle Scholar

Roche ME, Lin Z, Whitaker-Menezes D, Zhan T, Szuhai K, Bovee J, et al. Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165962.

ArticlePubMedPubMed CentralGoogle Scholar

Yang X, Song D, Zhang J, Yang X, Feng H, Guo J. PRR34-AS1 sponges miR-498 to facilitate TOMM20 and ITGA6 mediated tumor progression in HCC. Exp Mol Pathol. 2021;120:104620.

ArticlePubMedGoogle Scholar

Levesque MH, El-Alfy M, Cusan L, Labrie F. Androgen receptor as a potential sign of prostate cancer metastasis. Prostate. 2009;69:1704–11.

ArticlePubMedGoogle Scholar

Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y, et al. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer. J Exp Clin Cancer Res. 2023;42:204.

ArticlePubMedPubMed CentralGoogle Scholar

Li B, Lu W, Chen Z. Regulation of androgen receptor by E3 ubiquitin ligases: for more or less. Receptors Clin Investig. 2014;1:10.

Ratajczak W, Lubkowski M, Lubkowska A. Heat shock proteins in benign prostatic hyperplasia and prostate cancer. Int J Mol Sci. 2022;23:897.

Eftekharzadeh B, Banduseela VC, Chiesa G, Martinez-Cristobal P, Rauch JN, Nath SR, et al. Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor. Nat Commun. 2019;10:3562.

ArticlePubMedPubMed CentralGoogle Scholar

Schleiff E, Turnbull JL. Characterization of the N-terminal targeting signal binding domain of the mitochondrial outer membrane receptor, Tom20. Biochemistry. 1998;37:13052–8.

ArticlePubMedGoogle Scholar

Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018;28:1171–85.

ArticlePubMedPubMed CentralGoogle Scholar

Lalier L, Mignard V, Joalland MP, Lanoe D, Cartron PF, Manon S, et al. TOM20-mediated transfer of Bcl2 from ER to MAM and mitochondria upon induction of apoptosis. Cell Death Dis. 2021;12:182.

ArticlePubMedPubMed CentralGoogle Scholar

Fu ZJ, Wang ZY, Xu L, Chen XH, Li XX, Liao WT, et al. HIF-1alpha-BNIP3-mediated mitophagy in tubular cells protects against renal ischemia/reperfusion injury. Redox Biol. 2020;36:101671.

ArticlePubMedPubMed CentralGoogle Scholar

Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93:233–41.

ArticlePubMedGoogle Scholar

Tkac J, Gajdosova V, Hroncekova S, Bertok T, Hires M, Jane E, et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus. 2019;9:20180077.

ArticlePubMedPubMed CentralGoogle Scholar

Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003;30:709–16.

ArticlePubMedGoogle Scholar

Chen L, Li J, Farah E, Sarkar S, Ahmad N, Gupta S, et al. Cotargeting HSP90 and its client proteins for treatment of prostate cancer. Mol Cancer Ther. 2016;15:2107–18.

ArticlePubMedPubMed CentralGoogle Scholar

Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, et al. Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer. Cancer Res. 2018;78:4022–35.

ArticlePubMedPubMed CentralGoogle Scholar

Download references

Funding

This study was funded by the National Natural Science Foundation of China (NSFC 81572542, NSFC 81874096), Research Project of Key Discipline of Guangdong Province (2019GDXK0010), Science and Technology Program of Guangzhou City (202102021130), National Key Specialty Construction Project of Clinical Pharmacy, High Level Clinical Key Specialty of Clinical Pharmacy in Guangdong Province, and Key Engineering Team, Discipline Cultvation Projects, Guangdong Pharmaceutical University (2024ZZ10).

Author information

Authors and Affiliations

Key Laboratory of Clinical Precision Pharmacy of Guangdong Higher Education Institutes, The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, 510699, China

Linglong Yin, Yi Dai, Yue Wang, Shiwen Liu, Yubing Ye, Yongming Fu, Yuchong Peng, Li Fang, Haoran Suo & Xiong Li

Key Specialty of Clinical Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, 510699, China

Linglong Yin, Yi Dai, Yue Wang, Shiwen Liu, Yubing Ye, Yongming Fu, Yuchong Peng, Li Fang, Haoran Suo & Xiong Li

NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, 510006, China

Linglong Yin, Yi Dai, Yue Wang, Shiwen Liu, Yubing Ye, Yongming Fu, Yuchong Peng, Li Fang, Haoran Suo & Xiong Li

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China

Linglong Yin, Yi Dai, Yue Wang, Shiwen Liu, Li Fang & Haoran Suo

BaiSheng (GuangZhou) Biological Products Co. Ltd., Guangzhou, China

Ruizheng Tan

School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, China

Xuli Qi & Xiong Li

Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China

Bowen Yuan

Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China

Yingxue Gao

Xiangya Cancer Center, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China

Youhong Liu

Authors

Linglong Yin

View author publications

You can also search for this author in PubMedGoogle Scholar

2. Yi Dai

View author publications

You can also search for this author in PubMedGoogle Scholar

3. Yue Wang

View author publications

You can also search for this author in PubMedGoogle Scholar

4. Shiwen Liu

View author publications

You can also search for this author in PubMedGoogle Scholar

5. Yubing Ye

View author publications

You can also search for this author in PubMedGoogle Scholar

6. Yongming Fu

View author publications

You can also search for this author in PubMedGoogle Scholar

7. Yuchong Peng

View author publications

You can also search for this author in PubMedGoogle Scholar

8. Ruizheng Tan

View author publications

You can also search for this author in PubMedGoogle Scholar

9. Li Fang

View author publications

You can also search for this author in PubMedGoogle Scholar

10. Haoran Suo

View author publications

You can also search for this author in PubMedGoogle Scholar

11. Xuli Qi

View author publications

You can also search for this author in PubMedGoogle Scholar

12. Bowen Yuan

View author publications

You can also search for this author in PubMedGoogle Scholar

13. Yingxue Gao

View author publications

You can also search for this author in PubMedGoogle Scholar

14. Youhong Liu

View author publications

You can also search for this author in PubMedGoogle Scholar

15. Xiong Li

View author publications

You can also search for this author in PubMedGoogle Scholar

Contributions

YLL:data collection and analysis, project development. DY:data collection and project development. WY, LSW, YYB, FYM, PYC, TRZ, FL, SHR, QXL, YBW, GYX, LYH: data collection and analysis. YLL and LX: manuscript writing. LX: idea development, data management and analysis and manuscript writing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xiong Li.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

supplement legend

Figure S1

Figure S2

Figure S3

Supplementary Table 1

Supplementary Table 2

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, L., Dai, Y., Wang, Y. et al. A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells. Oncogene (2025). https://doi.org/10.1038/s41388-025-03328-w

Download citation

Received:22 September 2024

Revised:01 February 2025

Accepted:21 February 2025

Published:06 March 2025

DOI:https://doi.org/10.1038/s41388-025-03328-w

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative

Read full news in source page